Summit Therapeutics
Market cap $8.53B 799.8M shares (10-Q, Oct 30, 2026) × $10.67 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- ivonescimab NSCLC interim4Q 2026ivonescimab NSCLC interim, 4Q 2026, material
- HARMONi-GU1 corporate update4Q 2026HARMONi-GU1 corporate update, 4Q 2026, routine
- EA2251 / HARMONi-GU1 corporate update4Q 2026EA2251 / HARMONi-GU1 corporate update, 4Q 2026, routine
- Share authorization increase financingDec 31, 2026Share authorization increase financing, Dec 31, 2026, routine
- HARMONi-3 non-squamous readout1H 2027HARMONi-3 non-squamous readout, 1H 2027, notable
- AstraZeneca preferred stock lock-up corporatelate 2027AstraZeneca preferred stock lock-up corporate, late 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
Technology platforms
SCOPE IO · Lunit
AI-powered pathology platform for tumor microenvironment analysis using H&E whole-slide images; supports biomarker discovery, patient stratification, and immuno-oncology research
Capital (as filed)
- Cash
- $151M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $479M Sep 30, 2026
- Operating cash flow
- −$160M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $630M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure
Offering documents (3)
- 2026-07-23 424B5 · At-the-market program up to $380M
- 2026-06-10 424B5 · Preliminary prospectus
- 2026-06-09 S-3ASR · Shelf registration
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (22)
- 2026-11-17 UPDATE: Summit Therapeutics (SMMT) - The CRL Lands 🔒 Paid
- 2026-11-05 UPDATE: Summit Therapeutics (SMMT) - Clearing the Desk Before the Binary
- 2026-10-27 UPDATE: Summit Therapeutics (SMMT) - The Biliary Number Arrives ★ Distilled Pro
- 2026-10-02 UPDATE: Summit Therapeutics (SMMT) - The MOU Gets a Phase III 🔒 Paid
- 2026-09-30 UPDATE: Summit Therapeutics (SMMT) - The Fine Print Behind the $2 Billion 🔒 Paid
- 2026-09-29 UPDATE: Summit Therapeutics (SMMT) - AstraZeneca Writes a $2 Billion Check 🔒 Paid
- 2026-09-16 UPDATE: Summit Therapeutics (SMMT) - The Western Confidence Interval Crosses One 🔒 Paid
- 2026-09-15 UPDATE: Summit Therapeutics (SMMT) - The Hazard Ratio Arrives 🔒 Paid
- 2026-09-02 UPDATE: Summit Therapeutics (SMMT) - Keytruda Just Lost a Head-to-Head on Survival 🔒 Paid
- 2026-08-25 UPDATE: Summit Therapeutics (SMMT) - The Drug Escapes the Lung 🔒 Paid
- 2026-08-13 UPDATE: Summit Therapeutics (SMMT) - China Says Yes, Round Three 🔒 Paid
- 2026-07-23 UPDATE: Summit Therapeutics (SMMT) - The Form 4s Landed 🔒 Paid
- 2026-07-22 UPDATE: Summit Therapeutics (SMMT) - The Western OS Number Just Caught Up 🔒 Paid
- 2026-06-11 UPDATE: Summit Therapeutics (SMMT) - The Deal Got Pulled 🔒 Paid
- 2026-06-09 UPDATE: Summit Therapeutics (SMMT) - The $500M Bait-and-Switch 🔒 Paid
- 2026-06-03 UPDATE: Summit Therapeutics (SMMT) - The Insiders Got the Green Light 🔒 Paid
- 2026-06-02 UPDATE: Summit Therapeutics (SMMT) - The Plenary Delivered. The Tape Didn’t. 🔒 Paid
- 2026-05-02 UPDATE: Summit Therapeutics (SMMT) - The 25% Panic Into ASCO 🔒 Paid
- 2026-05-01 UPDATE: Summit Therapeutics (SMMT) - Q1 2026 Earnings, an iDMC Pass, and an ASCO Plenary Slot 🔒 Paid
- 2026-03-29 UPDATE: Summit Therapeutics (SMMT) - ELCC 2026 Data 🔒 Paid
- 2026-03-01 UPDATE: Summit Therapeutics (SMMT) - EoY 2025 Update 🔒 Paid
- 2026-02-20 Summit Therapeutics (SMMT): Scientific Deep Dive for Ivonescimab and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (22 calls)
Every verdict Biotech Distilled has published on Summit Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-02-20 Buy core Summit Therapeutics (SMMT): Scientific Deep Dive for Ivonescimab and Pipeline Products Strong cooperative-binding science, historic insider conviction, and pristine cash runway make SMMT attractive despite FDA geographic data risk on the OS endpoint.
- 2026-03-01 Buy core UPDATE: Summit Therapeutics (SMMT) - EoY 2025 Update Accelerated HARMONi-3 interim catalyst and pristine balance sheet keep the thesis intact.
- 2026-03-29 Buy core UPDATE: Summit Therapeutics (SMMT) - ELCC 2026 Data Compelling intracranial efficacy data at ELCC strengthens the BLA package and the fundamental thesis.
- 2026-05-01 Buy core UPDATE: Summit Therapeutics (SMMT) - Q1 2026 Earnings, an iDMC Pass, and an ASCO Plenary Slot HARMONi-6 OS ASCO Plenary slot is a major catalyst escalation; thesis intact though asymmetry is shifting at higher price.
- 2026-05-02 Buy core UPDATE: Summit Therapeutics (SMMT) - The 25% Panic Into ASCO 25% single-session crash overdiscounts FDA risk; asymmetry has flipped back in the buyer's favor at $16.11.
- 2026-06-02 Buy core UPDATE: Summit Therapeutics (SMMT) - The Plenary Delivered. The Tape Didn't. HARMONi-6 OS HR 0.66 published in The Lancet validates the mechanism; at $15.71 the entry compensates for FDA risk more than at prior levels.
- 2026-06-03 Buy core UPDATE: Summit Therapeutics (SMMT) - The Insiders Got the Green Light Board clearing C-suite to buy through ATM at ~$15 is a confirmatory insider signal reinforcing the thesis.
- 2026-06-09 Hold UPDATE: Summit Therapeutics (SMMT) - The $500M Bait-and-Switch $500M underwritten offering at a punitive discount damages insider-signal credibility and creates near-term technical supply overhang, warranting a downgrade despite unchanged science.
- 2026-06-11 Buy core UPDATE: Summit Therapeutics (SMMT) - The Deal Got Pulled Withdrawal of the $500M offering removes the dilution trigger that caused the HOLD downgrade; asymmetry tilts back toward buyer at $13.08 though capital-structure uncertainty remains.
- 2026-07-22 Buy core UPDATE: Summit Therapeutics (SMMT) - The Western OS Number Just Caught Up Western OS HR converging to 0.76 at 23.2 months follow-up removes the post-hoc slicing critique and materially de-risks the FDA geography concern ahead of the PDUFA.
- 2026-07-23 Buy core UPDATE: Summit Therapeutics (SMMT) - The Form 4s Landed $52M of confirmed insider buying at $13.17 validates the June 3 signal; new $380M ATM and strong Q2 cash position secure runway through all near-term catalysts.
- 2026-08-13 Buy core UPDATE: Summit Therapeutics (SMMT) - China Says Yes, Round Three Third NMPA approval validates the HARMONi-6 dataset via regulatory audit; new HARMONi-GU1 bladder cancer Phase III extends the pipeline-in-a-product thesis.
- 2026-08-25 Buy core UPDATE: Summit Therapeutics (SMMT) - The Drug Escapes the Lung First non-lung Phase III OS win (HARMONi-GI1 vs. durvalumab in biliary cancer) and Lancet Oncology publication of HARMONi strengthen the platform case; WCLC September 15 is the next key catalyst.
- 2026-09-02 Buy core UPDATE: Summit Therapeutics (SMMT) - Keytruda Just Lost a Head-to-Head on Survival HARMONi-2 OS topline shows ivonescimab beating pembrolizumab on survival — the third head-to-head OS win over a checkpoint inhibitor — though no hazard ratio yet prevents an upgrade.
- 2026-09-15 Buy core UPDATE: Summit Therapeutics (SMMT) - The Hazard Ratio Arrives HARMONi-2 OS HR 0.73 vs. pembrolizumab with 0.58 in PD-L1-high subgroup is a strong HARMONi-7 prior; author maintains BUY but notes reduced asymmetry after 26% run and cautions against adding at $18.42.
- 2026-09-16 Hold UPDATE: Summit Therapeutics (SMMT) - The Western Confidence Interval Crosses One Western subgroup CI of 0.52–1.10 crosses 1.0 and global p-value is nominal; at $17.40 the price no longer compensates adequately for a genuine coin-flip FDA binary 60 days out.
- 2026-09-29 Buy core UPDATE: Summit Therapeutics (SMMT) - AstraZeneca Writes a $2 Billion Check AstraZeneca's $2B convertible preferred at an 18.6% premium transforms the CRL downside from 'busted binary' to 'delay with a war chest,' restoring the asymmetry in the buyer's favor.
- 2026-09-30 Buy core UPDATE: Summit Therapeutics (SMMT) - The Fine Print Behind the $2 Billion 8-K fine print confirms AZ has no veto over takeovers and is locked up for a year, removing supply overhang fears and supporting the BUY thesis.
- 2026-10-02 Buy core UPDATE: Summit Therapeutics (SMMT) - The MOU Gets a Phase III AZ/Daiichi Sankyo Phase III in TNBC with Datroway expands the pipeline-in-a-product thesis into breast cancer on capital-efficient terms without changing the November binary.
- 2026-10-27 Buy core UPDATE: Summit Therapeutics (SMMT) - The Biliary Number Arrives HARMONi-GI1 OS HR 0.75 with tight CI and a new U.S. registration-enabling trial (EA2251) strengthen the 'delayed not broken' downside case 19 days before the PDUFA.
- 2026-11-05 Buy core UPDATE: Summit Therapeutics (SMMT) - Clearing the Desk Before the Binary Going-concern warning removed, AZ conversion vote passed, and HARMONi-3 squamous PFS pinned to Q4; balance sheet questions settled ahead of the November 14 binary.
- 2026-11-17 Hold UPDATE: Summit Therapeutics (SMMT) - The CRL Lands FDA CRL confirms OS is the gate; molecule is intact but next approval opportunity depends on HARMONi-3 OS data months away, making adding before that readout unreasonable.
- Long call · opened Feb 20, 2026 at $15.94 · -33.1% vs XBI +16.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (7 quotes from 6 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The FDA provided a Prescription Drug User Fee Act (“PDUFA”) goal action date of November 14, 2026.”
matched to ivonescimab (2L+ EGFRm NSCLC) · regulatory decision · since happened Nov 15, 2026 / matched to ivonescimab (HARMONi-3, 1L Squamous NSCLC) · interim data
-
-
-
“The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.”
matched to ivonescimab (HARMONi-3, 1L Squamous NSCLC) · interim data
-
-
-
“Detailed results of the study were provided in September 2025, and a Biologics License Application (BLA) was submitted to the United States Food and Drug Administration (FDA) for marketing authorization, which the FDA accepted for filing in January 2026; the goal Prescription Drug User Fee Act (PDUFA) date is November 14, 2026.”
matched to ivonescimab (2L+ EGFRm NSCLC) · regulatory decision · since happened Nov 15, 2026 -
“Summit’s Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) is based on the results from the HARMONi trial and has a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.”
matched to ivonescimab (2L+ EGFRm NSCLC, HARMONi) · regulatory decision
-
-
-
“Detailed results of the study were provided in September 2025, and a Biologics License Application (BLA) was submitted to the United States Food and Drug Administration (FDA) for marketing authorization, which the FDA accepted for filing in January 2026; the goal Prescription Drug User Fee Act (PDUFA) date is November 14, 2026.”
matched to ivonescimab (2L+ EGFRm NSCLC) · regulatory decision · since happened Nov 15, 2026
-
-
-
“Detailed results of the study were provided in September 2025, and a Biologics License Application (BLA) was submitted to the United States Food and Drug Administration (FDA) for marketing authorization, which the FDA accepted for filing in January 2026; the goal Prescription Drug User Fee Act (PDUFA) date is November 14, 2026.”
matched to ivonescimab (2L+ EGFRm NSCLC) · regulatory decision · since happened Nov 15, 2026
-
-
-
“The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026.”
matched to ivonescimab (2L+ EGFRm NSCLC, HARMONi) · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (57)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 16, 20268-KCurrent report: other events · EX-99.1→ BD updateThe FDA said no: a CRL landed Saturday on the HARMONi BLA, citing the absence of a statistically significant OS benefit — exactly the regulatory trap I flagged in the original deep dive. The coin landed tails, but the molecule isn't dead and the war chest is intact.
- Nov 15, 2026ReleaseSummit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application→ BD updateSummary on the 8-K of Nov 16, 2026
- Nov 4, 2026ReleaseSummit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: results of operations, charter / bylaws / fiscal year, shareholder vote · EX-99.1→ BD updateSummary on the 8-K
- Nov 4, 20268-KCurrent report: other events→ BD updateWith the authorized-share vote cleared today and the PDUFA 10 days out, Summit enters its most consequential window yet — a fortified balance sheet, imminent HARMONi-3 squamous data, and a binary FDA decision all stacking into the same fortnight.
- Nov 4, 2026424B7Prospectus supplement→ BD updateSummary on the 8-K
- Nov 4, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 25, 2026ReleaseIvonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S→ BD updateThe HARMONi-GI1 blank I flagged in August finally got filled at ESMO 2026's Presidential Symposium — OS HR 0.75, p=0.0031, PFS HR 0.61, ORR 53.8% — and Summit simultaneously announced a Western registration-enabling BTC trial via ECOG-ACRIN, even as the stock continues bleeding ahead of the November 14 PDUFA.BD extracted 1 program update from this document → SMMT pipeline
- Oct 23, 2026ReleaseSummit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
- Oct 22, 2026ReleaseIvonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
- Oct 21, 2026ReleaseSummit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
- Oct 19, 2026ReleaseSummit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell CarcinomaBD extracted 1 program update from this document → SMMT pipeline
- Oct 19, 2026DEF 14AProxy statement
- Oct 5, 2026ReleaseAstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
- Oct 2, 2026ReleaseSummit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway→ BD updateSummit, AstraZeneca, and Daiichi Sankyo just signed a three-way collaboration to run a Phase III trial of ivonescimab + Datroway in first-line triple-negative breast cancer — the first breast cancer push for ivonescimab, and the seventh capital-efficient partnership that expands the "pipeline in a product" thesis without Summit footing the whole bill.
- Sep 29, 20268-KCurrent report: material agreement, unregistered sale of equity, charter / bylaws / fiscal year · EX-99.1→ BD updateAstraZeneca just wrote a $2 billion check at $18.36/share — a premium to market — and signed a clinical collaboration on Claudin 18.2 ADC combinations with ivonescimab. The going-concern overhang that haunted this name since May is now functionally dead, and a top-tier pharma oncology team has put its balance sheet behind the same data the FDA will rule on in 47 days.
- Sep 28, 2026ReleaseAstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics→ BD updateAstraZeneca just wrote a $2 billion check for Summit at $18.36/share — a 19% premium to today's close — validating the ivonescimab thesis in the strongest possible currency, 47 days before the FDA's decision.
- Sep 22, 2026ReleaseHARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to BeBD extracted 1 program update from this document → SMMT pipeline
- Sep 15, 2026ReleaseUpdated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients→ BD updateSummary on the 8-K
- Sep 15, 20268-KCurrent report: other events · EX-99.1→ BD updateThe WCLC data Summit's FDA reviewers have been waiting for just landed: HARMONi's Western OS hazard ratio has converged to 0.76 at 23.2 months of follow-up, matching the global ITT exactly — and the full HARMONi-2 numbers vs. Keytruda arrived with them. The stock is selling off anyway, and that disconnect deserves a close read.BD extracted 1 program update from this document → SMMT pipeline
- Sep 14, 20268-KCurrent report: other events · EX-99.1→ BD updateThe HARMONi-2 OS numbers have landed at WCLC 2026: HR 0.73 (95% CI 0.57–0.95; p=0.009), median OS 30.8 vs. 22.6 months — a 27% reduction in the risk of death vs. pembrolizumab, with the PD-L1-high subgroup posting an HR of 0.58 that speaks directly to HARMONi-7's design.BD extracted 1 program update from this document → SMMT pipeline
- Sep 13, 2026ReleaseIvonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Condu→ BD updateSummary on the 8-K of Sep 14, 2026BD extracted 1 program update from this document → SMMT pipeline
- Sep 3, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → SMMT pipeline
- Sep 2, 2026ReleaseIvonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in→ BD updateAkeso's HARMONi-2 just delivered what no trial has done before: ivonescimab monotherapy beat Keytruda monotherapy on overall survival in PD-L1-positive NSCLC — the third OS win over an approved checkpoint inhibitor, 73 days before the FDA PDUFA.BD extracted 1 program update from this document → SMMT pipeline
- Aug 26, 20268-KCurrent report: other events · EX-99.1
- Aug 25, 2026ReleaseIvonescimab Plus Chemotherapy Global Phase III HARMONi Primary Analysis Results Published in The Lancet Oncology→ BD updateSummary on the releaseBD extracted 1 program update from this document → SMMT pipeline
- Aug 25, 2026ReleaseIvonescimab Plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Durvalumab Plus Chemotherapy in First-Line Advanced Biliary Tract Cancer in Single-Region Tria→ BD updateTwo catalysts landed today: HARMONi goes peer-reviewed in The Lancet Oncology with the WCLC updated OS presentation now confirmed for September 15, and Akeso's HARMONi-GI1 becomes the first ivonescimab Phase III win outside NSCLC — OS superiority over an active PD-L1 in biliary tract cancer. Five-for-five on Phase III readouts, 81 days before the PDUFA that counts.
- Aug 12, 2026ReleaseIvonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung CancerBD extracted 2 program updates from this document → SMMT pipeline
- Aug 5, 2026ReleaseSummit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer
- Aug 5, 20268-KCurrent report: other events · EX-99.1
- Jul 23, 2026ReleaseSummit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
- Jul 23, 20268-KCurrent report: results of operations, Reg FD disclosure · EX-99.1
- Jul 23, 20268-KCurrent report: material agreementBD extracted 1 program update from this document → SMMT pipeline
- Jul 23, 2026424B5Prospectus supplement (offering)
- Jul 23, 202610-QQuarterly reportBD extracted 1 program update from this document → SMMT pipeline
- Jul 22, 2026ReleaseIvonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
- Jul 22, 2026ReleaseArcus Biosciences and Summit Therapeutics Enter into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney CancerBD extracted 1 program update from this document → SMMT pipeline
- Jul 22, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → SMMT pipeline
- Jul 14, 2026ReleaseSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
- Jun 12, 20268-KCurrent report: shareholder vote
- Jun 11, 20268-KCurrent report: Reg FD disclosure
- Jun 10, 2026424B5Prospectus supplement (offering)
- Jun 9, 2026S-3ASRAutomatic shelf registration
- Jun 9, 2026ReleaseSummit Therapeutics Announces Proposed Public Offering of Common Stock
- Jun 4, 2026ReleaseSummit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
- Jun 3, 20268-KCurrent report: other events
- Jun 1, 20268-KCurrent report: other events · EX-99.1BD extracted 1 program update from this document → SMMT pipeline
- May 31, 2026ReleaseIvonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON
- May 30, 2026ReleaseEncouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
- Apr 30, 2026ReleaseShare on Facebook (opens in new window)
- Apr 30, 2026ReleaseShare on Linkedin (opens in new window)
- Apr 30, 2026ReleaseShare on Twitter (opens in new window)
- Apr 30, 2026ReleaseShare on Whatsapp (opens in new window)
- Apr 30, 20268-KCurrent report: results of operations · EX-99.1
- Apr 30, 202610-QQuarterly report
- Apr 17, 2026DEFA14AProxy soliciting material
- Apr 17, 2026DEF 14AProxy statement